Methods and compositions for treating Huntington's disease
申请人:Hung David
公开号:US20070117834A1
公开(公告)日:2007-05-24
The invention provides method for treating Huntington's disease, slowing the onset and/or development and/or progression of Huntington's disease or preventing the development of Huntington's disease using hydrogenated pyrido[4,3-b]indoles, including dimebon.
METHODS AND COMBINATION THERAPIES FOR TREATING ALZHEIMER'S DISEASE
申请人:Hung David T.
公开号:US20100152108A1
公开(公告)日:2010-06-17
The invention provides methods and combination therapies for treating and/or preventing and/or slowing the onset and/or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.
The invention relates to a salt of 3-methyl-1 -phenyl-2-pyrazolin-5-one (edaravone), wherein the salt is 3-methyl-1 -phenyl-2-pyrazolin-5-one napadisylate or 3-methyl-1 -phenyl-2- pyrazolin-5-one hemi-napadisylate. These napadisylate salts of edaravone are easy to manufacture and dissolve more rapidly in water than the free edaravone base. In addition, the edaravone salts of the present invention are very stable and easy to handle. The invention also relates to a pharmaceutical composition comprising the aforementioned edaravone salt and to a method of preparing such edaravone salt.
An organic electroluminescent element comprising a pair of electrodes composed of an anode and a cathode, a light-emitting layer provided between the electrodes, and a functional layer provided between the light-emitting layer and the anode, wherein the functional layer comprises an n-type semiconductor and a macromolecular compound comprising a repeating unit having an amine residue.